Crescent Biopharma, Inc. (CBIO) stock
Close on Nov 11, 2026Market cap $548.06MP/E –Yield –
Crescent Biopharma, Inc. reported revenue of $10.84M for fiscal 2025. Free cash flow was -$73.62M. At the latest close the market valued the company at $548.06M.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- $548.06M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 3.36
- Dividend yield
- –
- Free cash flow yield
- -13.43%
Fundamentals
- Revenue
- $10.84M
- Net income
- -$96.03M
- Free cash flow
- -$73.62M
Trading
- Next earnings
- Q3 FY2026, expected soon
- Previous close
- $13.92
- Open
- $13.74
- Day's range
- $13.65 – $15.00
- Volume
- 269,518
- Average volume (20 days)
- 230,241
- Beta (5 years)
- 1.63
- 52-week range
- $8.72 – $27.41
- RSI (14 days)
- 57.5
- Volatility (1 year)
- 81.0%
- Relative volume
- 0.77×
- WACC
- 13.0%
Market cap history
Month-end market cap since 2014, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | CBIO | S&P 500 | Difference | CBIO per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -1.0% | -2.4% | +1.4 pts | ||
| 3 months | -11.6% | -1.2% | −10.4 pts | ||
| Year to date | +24.4% | +12.3% | +12.1 pts | ||
| 1 year | +11.4% | +12.4% | −1.1 pts | ||
| 3 years | -87.7% | +78.8% | −166.5 pts | -50.3% | +21.4% |
| 5 years | -92.1% | +75.2% | −167.2 pts | -39.8% | +11.9% |
| 10 years | -97.6% | +311.1% | −408.7 pts | -31.1% | +15.2% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Crescent Biopharma filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- News
- News
- Results
- Results
- Update
About Crescent Biopharma
Pharmaceutical Preparations
The company is a clinical-stage biotechnology company that discovers and develops therapies for the treatment of cancer. Its pipeline includes CR-001, a bispecific antibody designed to bind both PD-1 and VEGF pathways to inhibit immune checkpoints and angiogenesis. It also develops antibody-drug conjugates, such as CR-002, a PD-L1-targeted conjugate delivering a topoisomerase toxin, and CR-003, an integrin beta-6-directed conjugate. The firm focuses on solid tumor oncology indications, including lung, colorectal, and gynecologic malignancies. Its end users are cancer patients with solid tumors requiring monotherapy or combination oncology treatments.
Company profile, executives and historyCrescent Biopharma stock: common questions
What is Crescent Biopharma's stock price?
CBIO closed at $14.76 on Nov 11, 2026, up 6.00% on the day. Over the past 52 weeks it traded between $8.72 and $27.41.
What is Crescent Biopharma's market cap?
Crescent Biopharma was worth $548.06M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
How much revenue does Crescent Biopharma make?
Crescent Biopharma reported revenue of $10.84M for fiscal 2025.
Does Crescent Biopharma pay a dividend?
No. Crescent Biopharma has not paid a cash dividend over the last twelve months.
When does Crescent Biopharma report earnings next?
Crescent Biopharma's Q3 FY2026 results are due soon; the company has not yet filed them with the SEC.
How has CBIO stock performed over the past year?
Including dividends, CBIO returned +11.4% over the past year, against +12.4% for the S&P 500.
How many CBIO shares are sold short?
4M shares were sold short at the latest FINRA report, 18.26% of the float, or 16.3 days of average trading volume.
Who are Crescent Biopharma's competitors?
Companies most similar to Crescent Biopharma by business, industry and size include PYXS, APLM, ADAG, WHWK, CTMX.
See a number that looks wrong?